Publications by authors named "D A Hsia"
Article Synopsis
- The study aimed to compare the risk of hypoglycemia among type 2 diabetes patients on metformin and adding one of four common therapies: glargine, glimepiride, liraglutide, or sitagliptin.
- The trial included 5,047 participants, assessing severe hypoglycemia events and symptoms over an average of 5 years, with a per-protocol analysis of 4,830 who completed follow-ups.
- Results showed that glimepiride had the highest incidence of severe hypoglycemia (1.3%), while liraglutide and sitagliptin had the lowest risks, indicating varying hypoglycemia likelihood based on the second medication added
Objective: To determine whether the relationship between average glucose (AG) levels and hemoglobin A1c (HbA1c) differs across racial/ethnic groups.
Research Design And Methods: We performed a prospective substudy of GRADE, a comparative effectiveness randomized trial conducted in 36 centers in the U.S.
Anti-obesity medications (AOMs) have emerged as one element of comprehensive obesity clinical care intended to improve long-term health outcomes for children and adolescents. The number of pediatric AOM clinical trials has burgeoned in recent years as new pharmacotherapeutics have been developed. Factors related to growth and development in children and adolescents can present unique challenges in terms of designing and conducting clinical trials investigating the safety and efficacy of AOMs.
View Article and Find Full Text PDFArticle Synopsis
- Research highlights a critical gap in understanding long COVID (PASC) in children and emphasizes the need for studies that define its characteristics in this age group.
- The objective is to identify common prolonged symptoms in children aged 6 to 17 post-SARS-CoV-2 infection, examining differences between school-age kids and adolescents, as well as potential symptom clusters for future research.
- A multicenter study involved nearly 5,000 participants, revealing that certain symptoms were significantly more prevalent in those with a history of COVID-19 compared to those without.
Recent advancements in immunology and islet biology have unveiled remarkable prospects for the postponement of Type 1 diabetes (T1D) through the strategic modulation of the immune system. In this Perspective, we discuss the pharmaceutical strides achieved, traversing from pre-clinical validation to the execution of impactful clinical trials. We begin with the initial investigations involving cyclosporine and glucocorticoids in rodent models, such as the non-obese diabetic (NOD) mouse, which guided early clinical trials.
View Article and Find Full Text PDF